We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$980M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+25.82%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$183M
AUM Growth
+$11.2M
(+6.5%)
Cap. Flow
+$12.8M
Cap. Flow
% of AUM
7.01%
Top 10 Holdings %
Top 10 Hldgs %
33.05%
Holding
110
New
26
Increased
27
Reduced
30
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
+$9.45M |
| 2 |
Aclaris Therapeutics
ACRS
|
+$6.59M |
| 3 |
MRUS
Merus
MRUS
|
+$5.65M |
| 4 |
RACB
Research Alliance Corp. II Class A Common Stock
RACB
|
+$5.12M |
| 5 |
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
|
+$4.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vericel Corp
VCEL
|
+$7.21M |
| 2 |
EPIX
ESSA Pharma
EPIX
|
+$5.8M |
| 3 |
Delcath Systems
DCTH
|
+$5.74M |
| 4 |
Sutro Biopharma
STRO
|
+$4.02M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$2.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.57% |
| 2 | Financials | 3.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
101
Sutro Biopharma
STRO
$401M
| – | – |
-18,500
| Closed | -$4.02M |
|
|
YARW
102
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
| – | – |
-97
| Closed | -$552K |
|
103
Zentalis Pharmaceuticals
ZNTL
$337M
| – | – |
-10,000
| Closed | -$519K |
|
104
Zymeworks
ZYME
$1.61B
| – | – |
-30,834
| Closed | -$1.46M |
|
|
BNGOW
105
DELISTED
Bionano Genomics, Inc. Warrant
BNGOW
| – | – |
-10,000
| Closed | -$21K |
|
|
APTX
106
DELISTED
Aptinyx Inc. Common Stock
APTX
| – | – |
-107,536
| Closed | -$372K |
|
|
CALA
107
CALL
DELISTED
Calithera Biosciences, Inc
CALA
| – | – |
-7,500
| Closed | -$737K |
|
|
KDMN
108
DELISTED
Kadmon Holdings, Inc.
KDMN
| – | – |
-241,756
| Closed | -$1M |
|
|
ALXN
109
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-5,000
| Closed | -$781K |
|
|
CNST
110
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| – | – |
-25,200
| Closed | -$726K |
|
Similar funds
BIP
MVM
MFWP
FCM
KL
GFP
ADIC
PCM
Silverarc Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Silverarc Capital Management held 110 positions worth $183M, up 6.5% from $172M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Silverarc Capital Management deployed $12.8M of net new capital in Q1 2021, opening 26 new positions and adding to 27 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 500,000 shares worth $1.71M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Vericel Corp, an estimated $7.21M trimmed.
- Silverarc Capital Management's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 500,000 shares worth $1.71M.
- Silverarc Capital Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2021, an estimated $2.72M increase.
- Silverarc Capital Management's biggest Q1 2021 reduction was Vericel Corp, cutting an estimated $7.21M.
- Silverarc Capital Management fully exited Sutro Biopharma in Q1 2021, selling an estimated $4.02M.
- Silverarc Capital Management's ten largest holdings make up 33% of its $183M portfolio in Q1 2021.
- Silverarc Capital Management opened 26 new positions and closed 19 in Q1 2021.
- Silverarc Capital Management's portfolio value rose 6.5% quarter-over-quarter to $183M.
Based on Silverarc Capital Management's 13F filing for Q1 2021, filed 18 May 2021.